FDA Advisory Committee Votes Yes on BPC-157 and KPV — Against Its Own Staff's Recommendation

What Happened Today

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that BPC-157 and KPV be added to the 503A bulks list — the list that allows licensed compounding pharmacies to prepare and dispense these substances legally.

The vote on BPC-157: 8 yes, 6 no, 1 abstain.

The vote on KPV: passed with similar margins.

This is a significant moment. It is unprecedented for an FDA advisory panel to vote in favor of a substance that FDA staff explicitly recommended against. The agency’s own briefing documents stated that the evaluation criteria “weigh against” placing either compound on the 503A list. The committee voted yes anyway.

The meeting continues July 24, when the committee will consider Emideltide, Semax, and Epitalon.

---

What the 503A List Actually Means

The 503A bulks list is the legal pathway by which compounding pharmacies can prepare substances for individual patients based on a valid prescription. Inclusion on this list does not mean FDA approval — it means licensed compounding pharmacies can prepare the substance without going through the standard drug approval process.

This is meaningfully different from full FDA approval:

• Compounding pharmacies are regulated primarily by state boards of pharmacy, not FDA
• The compounds are prepared per-patient, not manufactured at scale under FDA GMPs
• Inclusion on the 503A list does not generate the clinical trial evidence base that a standard NDA approval requires

What today’s vote does: it creates a formal pathway for practitioners to prescribe BPC-157 and KPV through licensed compounding pharmacies, removing the current gray-market status that has pushed users toward unregulated suppliers.

---

Why FDA Staff Said No

FDA’s briefing documents were direct. On BPC-157, staff found:

• Limited clinical evidence: The only trial for BPC-157 in ulcerative colitis (its evaluated indication) was a meeting abstract reporting on 46 patients using rectal enema administration — not injection
• Existing approved alternatives: FDA-approved treatments for ulcerative colitis exist, which weighs against 503A placement
• Impurity and characterization concerns: Peptide-related manufacturing impurities are a known safety risk at compounding scale

On KPV, staff found:

• No human trials: None of the studies evaluated were conducted in humans
• Wound healing and inflammatory conditions have approved treatment options

FDA’s position has been consistent since 2023, when it essentially banned compounding pharmacies from dispensing BPC-157 and six other peptides, citing “significant safety risks.”

---

Why the Committee Voted Yes Anyway

This is where it gets complicated.

Several committee members argued that the practical alternative — patients sourcing peptides from gray-market suppliers, including Chinese manufacturers — poses greater safety risks than allowing licensed pharmacies to prepare them under controlled conditions.

“As a physician, I have to make sure that I’m keeping patients as safe as possible. When I look at saying no to this and pushing it to the gray market, am I doing greater harm? That’s why I lose sleep at night.” — Dr. Haleem Mohammed, CMO, Gameday Men’s Health (voted yes)

The harm reduction argument was the dominant “yes” rationale: if the substance is being used regardless, regulated compounding is safer than unregulated sourcing.

Critics noted that many of the “yes” votes came from committee members who consult with or are employed by telehealth companies that stand to benefit financially from widespread peptide access. This is a notable departure from typical PCAC composition, which has historically skewed toward academics and researchers.

---

The Conflict of Interest Question

Multiple outlets reported that many voting committee members have direct ties to companies that could profit from this decision. The American Academy of Peptide Medicine, an industry group that lobbied for inclusion on the list, described the vote as restoring “medical freedom.”

Major telehealth platforms testified in favor of the vote. Hims & Hers stock rose more than 10% after the BPC-157 vote. Financial analysts have projected a $2.2 billion telehealth marketing opportunity if all seven peptides under consideration are ultimately approved for compounding.

The committee’s composition and the financial stakes involved are already drawing scrutiny from public health groups, including Public Citizen’s Health Research Group, which testified against inclusion.

---

What Happens Next

Today’s vote is not a binding decision. The formal pathway from here:

1. Committee recommendation goes to FDA
2. FDA initiates a public rulemaking process to formally add substances to the 503A list
3. Public comment period opens
4. FDA publishes a final rule

This is a multi-month process at minimum. BPC-157 and KPV are not immediately legal to compound as of today. The gray market status persists until rulemaking is complete.

FDA is not legally bound to follow the committee’s recommendation, though it typically does. Given that this recommendation went against FDA staff’s own position, the agency’s response will be worth watching closely.

---

The Full July 23–24 Agenda

Peptide	Indication Evaluated	Day
BPC-157	Ulcerative colitis	July 23 ✓
KPV	Wound healing, inflammatory conditions	July 23 ✓
TB-500	Wound healing	July 23
MOTS-C	Obesity, osteoporosis	July 23
Emideltide	Opioid withdrawal, chronic insomnia, narcolepsy	July 24
Semax	Cerebral ischemia, migraine, trigeminal neuralgia	July 24
Epitalon	Insomnia	July 24

Results for TB-500 and MOTS-C will follow on July 23. Emideltide, Semax, and Epitalon votes are scheduled for July 24.

---

What It Means for Practitioners and Patients

If rulemaking ultimately completes:

• BPC-157 and KPV would be legally prescribable through licensed 503A compounding pharmacies
• Practitioners could prescribe without operating in a legal gray area
• Quality and preparation standards would fall under state pharmacy board oversight — still less rigorous than FDA GMPs, but meaningfully more regulated than current gray-market sourcing

What it doesn’t change:

• The underlying evidence base — BPC-157 still lacks large-scale human clinical trial data
• FDA’s approved alternatives for the evaluated indications (UC, wound healing)
• The manufacturing quality differences between licensed compounders and unregulated suppliers

The harm reduction question is real and not resolved by this vote. Patients are currently sourcing these compounds regardless of legal status. Whether regulated compounding access reduces or increases overall risk depends heavily on how pharmacy boards enforce preparation standards.

---

Ercle’s Position

We’ve always said the evidence on BPC-157 is compelling at the preclinical level and limited at the human clinical level. Nothing about today’s vote changes that underlying science.

What changed today is the regulatory trajectory. This is the most significant shift in the U.S. peptide regulatory landscape since the 2023 ban. The pathway from gray market to licensed pharmacy is now formally in motion — but it is not complete, and the science still needs to catch up to the clinical enthusiasm.

We’ll cover the July 24 votes and any FDA response as they develop.

---

Sources: Time · FDA PCAC Meeting Materials · FDA Briefing Documents for BPC-157 (FDA) and KPV (FDA)